CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer
Claudia Paret(German Cancer Research Center), Uğur Şahin(Johannes Gutenberg University Mainz)
Cited by 81
Related Papers
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
|Nature|2021|828
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
|Nature|2021|735